Empowering Pharmacists: Enhancing RSV Knowledge and Vaccine Advocacy : Episode 1

Adjuvant RSV Vaccine in Older Adults

June 25, 2024

Opinion

Video

Carrie Koenigsfeld, PharmD, FAPhA, reviews the pivotal findings from the AReSVi-006 trial that supported the approval of the adjuvanted RSV vaccine, including its efficacy in preventing lower respiratory tract RSV, associated adverse events, and important study limitations that may have influenced the results.

Now Viewing

EP: 1.Adjuvant RSV Vaccine in Older Adults

EP: 2.Non-adjuvant RSV Vaccine in Older Adults

While the follow-up data for the AReSVi-006 trial have not been published, what key results thus far have led to the approval of the adjuvanted vaccine?
1. Efficacy of preventing RSV-related lower respiratory tract disease
2. Adverse effects
3. Trial limitations